Advanced

摘要： The concept and strategy of advanced gastric cancer treatment have gradually undergone profound changes with the in-depth understanding of the biology and heterogeneous characteristics of gastric cancer.Moreover,the development and application of new anticancer drugs,including chemotherapy drugs,molecularly targeted drugs and immunotherapy drugs for advanced gastric cancer are reported.The connotation of conversion therapy refers to the unresectable or borderline resectable tumors for surgical technical and/or oncological reasons,after active and effective chemotherapy and other comprehensive treatment,the primary gastric lesions can be reduced to a lower stage,while the metastatic lesions can be effectively controlled,to achieve R0 resection and improve the long-term survival rate.Current promising research results of conversion therapy are mostly from single-arm phase II clinical studies with small samples or retrospective studies.Conversion therapy still faces many challenges,including limited diagnostic and assessment methods,insufficient evidence of highly effective treatment regimens,difficulty in clarifying surgical indications,etc.Therefore,the integrated conversion therapy for advanced gastric cancer needs to be carried out with the close cooperation of a multidisciplinary team.Prospective,multi-center randomized controlled trial studies should be conducted in the future,and precision medicine such as molecular biology should be combined to provide better anticancer drug regimens and higher-level clinical evidence for conversion therapy of advanced gastric cancer.

摘要： KUKA工业机器人的应用范围非常广泛,官方软件KUKA.Sim Pro在中国的市场也越来越大。如何让KUKA.Sim Pro和西门子1500PLC通信,实现PLC和仿真软件进行数据交互一直是用户最关心的问题。本文通过测试KUKA.Sim Pro与S7-1500PLC的OPC UA通信,最终实现了KUKA.Sim Pro与S7-1500PLC的数据交互。

摘要： BACKGROUND Somatostatin analogues are an established first-line therapy for well differentiated small bowel neuroendocrine tumours(Wd-SBNETs),while and peptide receptor radionuclide therapy(PRRT)is frequently used as a second-line therapy.Adequate treatment selection of third-line treatment remains challenging due to the limited prospective data currently available on the best therapeutic sequence.AIM To understand current practice and rationale for decision-making by physicians in the 3rd-line setting by building an online survey.METHODS Weighted average(WA)of likelihood of usage between responders(1 very unlikely;4 very likely)was used to reflect the relevance of factors explored.RESULTS Replies from representatives of 28 centers were received(5/8/2020-21/9/2020);medical oncologist(53.6%),gastroenterologist(17.9%);United Kingdom(21.4%),Spain(17.9%),Italy(14.3%).Majority from European Neuroendocrine Tumor Society(ENETS)Centres of Excellence(57.1%),who followed ENETS guidelines(82.1%).Generally speaking,3rd-line treatment for Wd-SBNETs was:everolimus(EVE)(66.7%),PRRT(18.5%),liver embolization(LE)(7.4%)and interferon-alpha(IFN)(3.7%);chemotherapy(0%);decision was based on clinical trial data(59.3%),or personal experience(22.2%).EVE was most likely used if Ki-67<10%(WA 3.27/4)or age<70 years(WA 3.23/4),in the 3rd-line setting(WA 3.23/4);regardless of presence/absence of carcinoid syndrome(CS),rate of progression or extent of disease.Chemotherapy was mainly utilised only if rapid progression(within 6 mo)(WA 3.35/4),Ki-6710%-20%(WA 2.77/4),negative somatostatin receptor imaging(WA 2.65/4)or high tumour burden(WA 2.77/4);temozolomide or streptozocin was used with capecitabine or 5-fluorouracil(5-FU)(57.7%),FOLFOX(5-FU combined with oxaliplatin)(23.1%).LE was selected if presence of CS(WA 3.24/4)or Ki-67<10%(WA 2.8/4),after progression to other treatments(WA 2.8/4).IFN was rarely used(WA 1.3/4).CONCLUSION Everolimus was the most frequently used therapeutic option in the third-line setting.The most important factors for decision-making included Ki-67,rate of progression,functionality and tumour burden;since this decision is based on multiple factors,it highlights the need for a multidisciplinary assessment.

摘要： BACKGROUND Pelvic recurrence after rectal cancer surgery is still a significant problem despite the introduction of total mesorectal excision and chemoradiation treatment(CRT),and one of the most common areas of recurrence is in the lateral pelvic lymph nodes.Hence,there is a possible role for lateral pelvic lymph node dissection(LPND)in rectal cancer.AIM To evaluate the short-term outcomes of patients who underwent minimally invasive LPND during rectal cancer surgery.Secondary outcomes were to evaluate for any predictive factors to determine lymph node metastases based on pre-operative scans.METHODS From October 2016 to November 2019,22 patients with stage II or III rectal cancer underwent minimally invasive rectal cancer surgery and LPND.These patients were all discussed at a multidisciplinary tumor board meeting and most of them received neoadjuvant chemoradiation prior to surgery.All patients had radiologically positive lateral pelvic lymph nodes on the initial staging scans,defined as lymph nodes larger than 7 mm in long axis measurement,or abnormal radiological morphology.LPND was only performed on the involved side.RESULTS Majority of the patients were male(18/22,81.8%),with a median age of 65 years(44-81).Eighteen patients completed neoadjuvant CRT pre-operatively.18 patients(81.8%)had unilateral LPND,with the others receiving bilateral surgery.The median number of lateral pelvic lymph nodes harvested was 10(3-22)per pelvic side wall.8 patients(36.4%)had positive metastases identified in the lymph nodes harvested.The median pre-CRT size of these positive lymph nodes was 10 mm.Median length of stay was 7.5 d(3-76),and only 2 patients failed initial removal of their urinary catheter.Complication rates were low,with only 1 lymphocele and 1 anastomotic leak.There was only 1 mortality(4.5%).There have been no recurrences so far.CONCLUSION Chemoradiation is inadequate in completely eradicating lateral wall metastasis and there are still technical limitations in accurately diagnosing metastases in these areas.A pre-CRT lymph node size of≥10 mm is suggestive of metastases.LPND may be performed safely with minimally invasive surgery.

摘要： During the last decades,further knowledge of hepatocellular carcinoma(HCC)molecular mechanisms has led to development of effective systemic treatments including tyrosine kinase inhibitors(TKIs)and immunotherapy.In this review,we describe first and second line systemic treatment options for advanced HCC.Several trials have evaluated new drugs for the treatment of HCC patients:In first line,lenvatinib resulted non-inferior to sorafenib and it can be used as alternative,even in the lack of evidence for sequential treatment options in second line after lenvatinib.Recently,atezolizumab plus bevacizumab have shown superiority over sorafenib in first-line.Sorafenib-regorafenib sequential administration in selected patients has opened a new paradigm of treatment in advanced HCC with a life expectancy exceeding two years.Other TKIs for second line treatment include cabozantinib and ramucirumab(specifically for patients with Alpha-fetoprotein values≥400 ng/mL).The combination of TKIs with immunotherapy may represent a big step forward for these patients in the near future.

摘要： BACKGROUND There is increasing interest in transplanting patients with hepatocellularcarcinoma (HCC) with tumors greater than 5 cm (Milan criteria).AIM To investigate possible prognostically-useful factors for liver transplantation inHCC patients with large tumors.METHODS In this clinical study, 50 patients with HCC who were transplanted at our LiverTransplant Center between April 2006 and August 2019 and had tumors greaterthan 6 cm maximum diameter were retrospectively analyzed. Their survival andfull clinical characteristics were examined, with respect to serum alphafetoprotein(AFP) and gamma glutamyl transpeptidase (GGT) levels. Kaplan-Meier survival estimates were used to determine overall survival and disease-freesurvival in these patients. The inclusion criterion was evidence of HCC. Exclusioncriteria were the presence of macroscopic portal vein thrombosis or metastasisand a follow-up period of less than 90 d.RESULTS Using receiver operating characteristic curve (ROC) analysis, cutoff values of AFP200 ng/mL and GGT 104 IU/L were identified and used in this study.Significantly longer overall survival (OS) and disease-free-survival (DFS) were found in patients who had lower values of either parameter, compared withhigher values. Even greater differences in survival were found when the 2parameters were combined. Two tumor size bands were identified, in searchingfor the limits of this approach with larger tumors, namely 6-10 cm and > 10 cm.Combination parameters in the 6-10 cm band reflected 5-year OS of 76.2% inpatients with low AFP plus low GGT vs 0% for all other groups. Patients withtumors greater than 10 cm, did not have low AFP plus low GGT. The mostconsistent clinical correlates for longer survival were degree of tumordifferentiation and absence of microscopic portal venous invasion.CONCLUSION Serum levels of AFP and GGT, both alone and combined, represent a simpleprognostic identifier in patients with large HCCs undergoing liver transplantation.

摘要： BACKGROUND The reliability of preoperative nodal diagnosis of advanced gastric cancer by multi-detector spiral computed tomography(MDCT)is still unclear.AIM To examine the diagnostic ability of MDCT more precisely by using data on intranodal pathological metastatic patterns.METHODS A total of 108 patients with advanced gastric cancer who underwent MDCT and curative gastrectomy at Kanazawa Medical University Hospital were enrolled in this study.The nodal sizes measured on computed tomography(CT)images were compared with the pathology results.A receiver-operating characteristic curve was constructed,from which the critical value(CV)was calculated by using the data of the first 69 patients retrospectively.By using the CV,sensitivity and specificity were calculated with prospectively collected data from 39 consecutive patients.This enabled a more precise one-to-one correspondence of lymph nodes between CT and pathological examination by using the size data of lymph node mapping.The intranodal pathological metastatic patterns were classified into the following four types:Small nodular,peripheral,large nodular,and diffuse.RESULTS Although all the cases were clinically suspected as having metastasis,81 had lymph node metastasis and 27 had no metastasis.The number of dissected,detected on CT,and metastatic nodes were,4241,897,and 801,respectively.The CV obtained from the receiver-operating characteristic was 7.6 mm for the long axis.The sensitivity was 91.4%and the specificity was 47.3%in the prospective phase.The large nodular and diffuse metastases were easy to diagnose becausemetastatic nodes with a large axis often exhibit these forms.CONCLUSION The ability of MDCT to contribute to a nodal diagnosis of advanced gastric cancer was examined prospectively with precise size data from node mapping,using a CV of 7.6 mm for the long axis that was calculated from the retrospectively collected data.The sensitivity was as high as 91%,and would be improved when referring to the enhanced patterns.However,its specificity was as low as 47%,because most of metastatic nodes in gastric cancer being small in size.The small nodular or peripheral type metastatic nodes were often small and considered difficult to diagnose.

摘要： BACKGROUND Transarterial chemoembolization(TACE)and hepatic arterial infusion chemotherapy(HAIC)have shown promising local benefits for advanced hepatocellular carcinoma(HCC).S-1,a composite preparation of a 5-fluorouracil prodrug,has proven to be a convenient oral chemotherapeutic agent with definite efficacy against advanced HCC.AIM To evaluate the efficacy and safety of TACE followed by HAIC with or without oral S-1 for treating advanced HCC.METHODS In this single-center,open-label,prospective,randomized controlled trial,117 participants with advanced HCC were randomized to receive TACE followed by oxaliplatin-based HAIC either with(TACE/HAIC+S-1,n=56)or without(TACE/HAIC,n=61)oral S-1 between December 2013 and September 2017.Two participants were excluded from final analysis for withdrawing consent.The primary endpoint was progression-free survival(PFS)and secondary endpoints included overall survival(OS),objective response rate,disease control rate and safety.RESULTS In total,115 participants(100 males and 15 females;mean age,57.7 years±11.9)were analyzed.The median PFS and OS were 5.0 mo(0.4–58.6 mo)(95%confidence interval(CI):3.82 to 6.18)vs 4.4 mo(1.1–54.4 mo)(95%CI:2.54 to 6.26;P=0.585)and 8.4 mo(0.4–58.6 mo)(95%CI:6.88 to 9.92)vs 8.3 mo(1.4–54.4 m)(95%CI:5.71 to 10.96;P=0.985)in the TACE/HAIC+S-1 and TACE/HAIC groups,respectively.The objective response rate and disease control rate were 30.9%vs 18.4%and 72.7%vs 56.7%in the TACE/HAIC+S-1 and TACE/HAIC groups,respectively.Grade 3/4 adverse events had a similar frequency in both treatment groups.CONCLUSION No improvements in tumor response rates,PFS or OS were observed with the addition of S-1 to TACE/HAIC in advanced HCC.Both treatment regimens had a similar safety profile.

摘要： Dear readers,What do you think of when you hear the word "connected"? Maybe you think of things like technology;nature or relationships, just to name a few;There are many ways to be connected in our world. This month in Advanced well introduce topics that will help you stay connected.

摘要： The agate dyeing industry has been commonly seen as a high-pollution industry. Dyeing wastewater treatment is considered one of the most important categories for water-pollution control, because of its intense colour and the high concentration of organic contaminants. Most dyes used in the process present minimal biodegradability due to aromatic organic compounds in their structure. Using a photocatalytic reactor, experiments were carried out to study the decolorization of a water solution containing 8% ethylic alcohol and 200 mg L−1 of the dye Rhodamine B (RhB), the most difficult colorant to degrade among the used by the agate industry. The best conditions were further applied to treat the same agate water/ethyl alcohol solution containing a mixture of 200 mg L−1 of Rhodamine B (RhB), Crystal Violet (CV), Brilliant Green (BG), and Blood Red (BR). All the experiments were performed in a 2 L reactor equipped with ultraviolet (UV) lamps, at a wavelength of 365 nm, with powdered TiO2 or ZnO as the catalyst. The results indicated that the optimal decolorization conditions were attained with 2.5 g L−1 of the catalyst at pH 10 and an irradiation time of 80 min. The process resulted in complete degradation of CV, BG and 80% - 90% degradation of RhB and BR. The catalyst ZnO presented a performance somewhat better than TiO2. It is possible to conclude that the process of heterogeneous photocatalysis is effective for decolorization of water streams from the agate industry.

摘要： 本发明公开了一种基于LTE‑Advanced系统的随机接入过载控制方法，包括下行调度算法：遍历所有的无线承载，求和得到基站缓存区的待发送数据总量D

摘要： 本发明请求保护一种LTE‑Advanced Pro系统实现LWA功能的协议配置方法，首先在高层PDCP层将数据进行分载，传输到SeNB中，此时的SeNB也是能够支持WLAN的AP和AC辅小区，在辅小区上需要将局域网上的链路结构设计为能够识别PDCP PDU和无线承载标识的局域网，这样可以解决了WLAN的MAC中没有逻辑信道的概念，定义了新的适配层在PDCP层和MAC层之间，它可以在下行链路传输过来的PDCP包加上一定比特的ID指示以及可以区分LTE传输和WLAN传输的指示，这样便于在UE端识别各自数据的传输。在数据传输到UE端的高层PDCP处时，又通过LWA功能将两种无线传输过来的数据按序提交到上层。这样就通过LWA完成整个业务的传输。

摘要： 本发明公开了一种TD‑LTE/TD‑LTE‑Advanced基站射频一致性测试系统开关切换装置，包括多个双刀双掷开关、多个单刀双掷开关、多个双刀单掷开关、单刀三掷开关K3‑9。本发明通过软件控制不同开关连接通路，根据TD‑LTE/LTE‑Advanced基站射频一致性测试设备的要求，根据基站不同测试例的需求进行多开关组合控制切换，以满足TD‑LTE/LTE‑Advanced基站射频一致性测试系统众多仪表的快速调度，以及众多仪表的协同工作，同时保证了射频设计指标满足3GPP相关基站射频一致性要求。

摘要： 本发明公开了一种基于非信令的TD_LTE_Advanced基站信号分析装置及方法，属于信号测试领域，包括八路射频及中频通道，八路射频及中频通道连接有FPGA控制器和测量显示单元；通过各路射频通道，生成846.4MHz的模拟信号和153.6MHz的模拟中频信号，通过各路中频通道，进行模数转换，通过FPGA控制器对最佳采样数据进行时域分析、频域分析以及调制域分析，通过测量显示单元判断测试结果是否满足期望需求。本发明通过对八路射频数据、八路中频数据的分别处理，实现非信令情况下多天线，连续及非连续载波聚合的TD_LTE_Advanced基站信号的快速分析，简化了测试手段，提高了测试效率。

摘要： 本发明提供了一种LTE‑Advanced标准中低存储量Turbo码译码器及其设计方法，包括一重算模块，所述重算模块用于在前向状态度量计算出来后，需要编号为j＝0,2,5,7的前向状态度量值来计算后验概率时，这些度量值通过所述重算模块被重新计算出来，而只有编号为j＝1,3,4,6的前向状态度量值被存储在SMC中，从而使得SMC容量降低50％。本发明提出的适合反向重算的Max*函数与其反向重算，以及对应的硬件实现结构，由于SMC中只需存储一半的前向状态度量值，SMC的容量降低了50％，且引入的额外计算复杂度较低。

摘要： 本发明公开了一种LTE‑Advanced空中接口监测仪的解密装置及方法，属于移动通信系统信令监测领域，通过协议解析模块、密钥推演模块、解密算法模块和解密参数维护模块，在不接入核心网侧S6a/S10接口的情况下，解析出PDCP PDU、RRC PDU和NAS PDU，获取LTE‑Advanced的安全相关参数，并推演出AS/NAS解密过程的所有参数，能够实时对加密的AS/NAS数据进行解密，实现对LTE‑Advanced空中接口的实时无线监测。

摘要： 本发明公开了一种基于LTE‑Advanced中继系统的下行调度算法，用户业务数据更新；中继系统遍历所有的无线承载，求和得到基站缓存区的待发送数据总量q；然后进行新算法处理得到和q有密切关系的引入参数A和B；根据q和数据量阀值和的大小关系，阶段的采用不同的调度策略；策略包括：保持原算法的调度策略、选择提升实时业务的的调度优先级的策略或提升瞬时传输速率较高的实时业务的调度优先级的策略；把系统资源分配给调度用户；确定待传送用户业务数据格式，构建本次的调度信息，通过PDCCH信道发送给用户。与现有技术相比，本发明可以获得比改进前调度算法更高的吞吐量和更低的调度时延，充分利用资源，提升中继基站的性能。

摘要： 本发明公开了一种基于LTE-Advanced系统的随机接入过载控制方法，包括下行调度算法：遍历所有的无线承载，求和得到基站缓存区的待发送数据总量D

摘要： 本发明属于扫频接收机技术领域，尤其涉及一种LTE‑Advanced高速异步同步提取方法与装置：包括一个通用的空口信号分析平台，该分析平台包括射频单元、基带单元以及电源系统，还增加了一个异步粗同步单元；所述的异步粗同步单元由数据寄存器、可编程计数器和定时触发电路组成；系统内部自带时钟提供给AD变换器进行模数转换，同时AD的输出存储入数据RAM中保存。本发明在原有信号采集分析基础上，增加了一套时钟定时同步装置，再通过软件算法修正同步位置。具有以下优点：使得在室内进行LTE‑Advanced基站信号测试时，系统算法大大难度降低，减少了对硬件设备的压力，比如，可以选择容量较小的FPGA进行计算。可以对不同测量需求进行不同的延时设置，具有较宽的适应性。

摘要： 本实用新型公开了一种LTE_Advanced空口信号分析装置，所述空口射频信号通过四路端口输入四个混频模块进行分析，所述分析装置包括本振模块，混频模块，A/D控制模块，FPGA模块，ARM模块。本实用新型通过独立信号分析通道来分析不同天线端口的信号，采用多级FPGA模块化处理FFT(傅里叶变换)、同步、信道估计、信道均衡以及小区遍历搜索实现空信号的实时分析，采用RTOS系统的高速操作系统实现协议调度、基带处理以上下行空口信令分析，同时用户可以通过移动电脑，手机APP对本实用新型装置进行控制，在满足稳定空口信号分析的同时，也方便了用户。